IRCT20080728001031N27
Completed
Phase 1
Safety Assessment of Intracoronary Transplantation of Autologous Bone Marrow Derived Mononuclear Cells in Pediatric with Dilated Cardiomyopathy in Comparison with Control Group: Clinical Trial Phase I/II
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Royan Institute
- Enrollment
- 30
- Status
- Completed
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •LVEF\<45% (echocardiography)
- •Time of Diagnosis \> 3m
- •Resistance to Standard therapy \> 1m(Dig, ACE, Diuretic, BB)
Exclusion Criteria
- •Critical aortic stenosis
- •Severe coarctation
- •Coronary artery anomalies
- •Cardiogenic shock
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 1
Effect of wharton's jelly derived-mesenchymal stem cells in treatment of pediatric with cardiomyopathyIRCT20201217049743N1Celltech pharmed company5
Not yet recruiting
Not Applicable
The first safety study of a Bionic Vision Prosthesis in adults with complete and untreatable blindnessntreatable bilateral complete vision impairmentACTRN12618000014257Monash University3
Unknown
Phase 2
Transplantation of Autologous Cardiac Stem Cells in Ischemic Heart FailureHeart FailureNCT01758406Royan Institute50
Active, not recruiting
Phase 1
Klinische Studie zur intraarteriellen Transplantation von Knochenmarks-Progenitorzellen bei Patienten mit Diabetischer Neuropathie (Restoration of Nerve functions by Intra-arterial Transplantation of Bone Marrow Progenitor Cells in Patients with Diabetic Poly Neuropathy (PNP) - RENERVATEPatienten mit Symptomen einer distal symmetrischen diabetischen Polyneuropathie der Beine (Stadium 2). Typischerweise bestehen Schmerzen, sowie Parästhesien und Sensibilitätsstörungen and der unteren Extremität. Das Diabetische Fusssyndrom ist eine ernsthafte Komplikation durch Entstehung von UlceraEUCTR2005-000969-19-DEMedizinische Klinik III, Kardiologie20
Completed
Not Applicable
Assessment on safety of intravenously administered trastuzumab with 100 ml saline solution in HER2 positive breast cancerBreast cancerJPRN-UMIN000006710Shiga University of Medical Science30